阅读说明：本技术 Kras自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 (Application of KRAS autoantibody detection reagent in preparation of lung cancer screening kit ) 是由 张立 李为民 于 2019-12-06 设计创作，主要内容包括：本发明涉及体外诊断试剂领域,具体涉及KRAS自身抗体检测试剂在制备肺癌筛查试剂盒中的用途。本发明首次发现肺癌患者血清中KRAS蛋白的自身抗体水平显著低于肺部良性疾病患者。本发明将检测KRAS蛋白自身抗体的试剂用于制备肺癌筛查试剂盒,能够实现肺癌的有效筛查。(The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a KRAS autoantibody detection reagent in preparation of a lung cancer screening kit. The invention discovers for the first time that the level of the KRAS protein autoantibody in the serum of a lung cancer patient is obviously lower than that of a benign lung disease patient. According to the invention, the reagent for detecting the KRAS protein autoantibody is used for preparing the lung cancer screening kit, so that effective screening of lung cancer can be realized.)

1. Application of a reagent for detecting KRAS protein autoantibodies in preparation of a lung cancer screening kit.

2. The use of claim 1, wherein the reagent for detecting the KRAS protein autoantibody is a reagent for an enzyme linked immunosorbent assay or a combined immunoassay reagent.

3. The use of claim 1, wherein the reagent for detecting KRAS protein autoantibodies is a western blot reagent.

4. The use of claim 1, wherein the reagent for detecting KRAS protein autoantibodies is a reagent for protein chip detection methods.

5. The use of any one of claims 1 to 4, wherein the reagent for detecting KRAS protein autoantibodies is a reagent for detecting KRAS protein autoantibodies in human serum.

6. A lung cancer screening kit is characterized by comprising a reagent for detecting KRAS protein autoantibody.

7. The kit of claim 6, wherein the reagent for detecting the KRAS protein autoantibody is an enzyme-linked immunosorbent assay reagent or an enzyme-linked immunoassay reagent.

8. The kit of claim 6, wherein the reagent for detecting the KRAS protein autoantibody is a western blot reagent.

9. The kit of claim 6, wherein the reagent for detecting KRAS protein autoantibodies is a reagent for protein chip detection method.

10. The kit of any one of claims 5 to 9, wherein the reagent for detecting KRAS protein autoantibodies is a reagent for detecting KRAS protein autoantibodies in human serum.

Technical Field

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a KRAS autoantibody detection reagent in preparation of a lung cancer screening kit.

Background

Lung cancer is one of the most common malignant tumors in the world, the morbidity and mortality of the lung cancer are on the rising trend year by year, the morbidity is at the top of the world at present, and the health and the life of human beings are seriously threatened.

The lung cancer is a disease good in occult, clinical symptoms are often shown only when the disease develops to the advanced stage, 70-80% of lung cancer patients are already at the middle and advanced stages when the lung cancer symptoms are diagnosed, cancer cells are diffused, the best curing time is missed, and the five-year survival rate is low. For early-stage lung cancer patients, the survival rate and the survival quality of the patients can be greatly improved by 5 years and more through timely treatment. Early diagnosis of lung cancer and effective screening are therefore of paramount importance.

The screening of the lung cancer refers to that the conventional physical examination is carried out on people without lung cancer related symptoms, and the lung cancer is found in time before the symptoms appear. If the lung cancer molecular marker in the plasma can be found, the molecular marker has important significance for prompting a clinician to take relevant treatment measures or decisions for a patient at an early stage.

Autoantibodies are antibodies produced by the body to self-organs, cells or cellular components. At present, autoantibodies to certain proteins have become markers for lung cancer, such as: p53, NY-ESO-1, CYFRA, etc. (Tang Z-M, Link Z-G, WangC-M, Wu Y-B, Kong J-L (2017) Serum tune-associated autoimmune agents as diagnostic biologics for lung cancer: A systematic review and meta-analysis. PLoS ONE 12(7): e 0182117).

KRAS (gene sequence number: Ensembl: ENSG00000133703) has not been reported related to KRAS protein autoantibodies at present, and has not been known in the prior art related to lung cancer.

Disclosure of Invention

The invention aims to provide a novel autoantibody lung cancer marker and application of a detection reagent of the marker in preparation of a lung cancer screening kit.

The technical scheme of the invention comprises the following steps:

application of a reagent for detecting KRAS protein autoantibodies in preparation of a lung cancer screening kit.

As the application, the reagent for detecting the KRAS protein autoantibody is a reagent for an enzyme-linked immunosorbent assay or a combined immunoassay reagent.

As for the application, the reagent for detecting the KRAS protein autoantibody is a western blot reagent.

As mentioned above, the reagent for detecting KRAS protein autoantibody is a reagent for protein chip detection method.

As the aforementioned application, the reagent for detecting the KRAS protein autoantibody is a reagent for detecting the KRAS protein autoantibody in human serum.

A lung cancer screening kit, which comprises a reagent for detecting KRAS protein autoantibody.

As the kit, the reagent for detecting the KRAS protein autoantibody is a reagent for an enzyme-linked immunosorbent assay or an enzyme-linked immunoassay reagent.

According to the kit, the reagent for detecting the KRAS protein autoantibody is a western blot reagent.

As the kit, the reagent for detecting the KRAS protein autoantibody is a reagent for a protein chip detection method.

As the kit, the reagent for detecting the KRAS protein autoantibody is a reagent for detecting the KRAS protein autoantibody in human serum.

The key point of the invention is that the content of the KRAS autoantibody in the human blood is determined to be obviously related to the risk of lung cancer, so that the risk of lung cancer can be judged by detecting the content of the KRAS autoantibody in the human blood, and as for the specific means for detecting the KRAS autoantibody in the human blood, various means disclosed in the prior art can be adopted.

The invention provides a new lung cancer screening marker and a new lung cancer screening kit, which can realize effective screening of lung cancer; and the serum can be used as a detection sample, so that the harm to a patient is low. The invention has good application prospect.

Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.

The foregoing aspects of the present invention are explained in further detail below with reference to specific embodiments. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.

Hereinafter, "KRAS autoantibody" refers to "KRAS protein autoantibody".

Drawings

FIG. 1: comparison of KRAS autoantibody levels in serum of lung cancer patients (LC), benign lung Disease (DC).

FIG. 2: ROC analysis of lung cancer patients (LC) and benign lung Disease (DC).

Detailed Description